At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,281 enrolled
Drug / intervention
Alogliptin/Pioglitazonedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long-term Use of Alogliptin/Pioglitazone Combination Tablets in Patients With Type 2 Diabetes Mellitus
In Brief
An observational study evaluating Alogliptin/Pioglitazone for Type 2 Diabetes Mellitus. Completed, enrolled 3,281 participants across 1 site.
Detailed Summary
The purpose of this survey is to examine the safety and efficacy of long-term use of alogliptin/pioglitazone(Liovel) combination tablets in patients with type 2 diabetes mellitus determined as warranting combination therapy with alogliptin benzoate and pioglitazone hydrochloride
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2011
First PostedNov 2013
Primary CompletionMar 2015
TodayJul 2026
First PostedNov 21, 2013
Enrollment StartNov 28, 2011
Primary CompletionMar 31, 2015
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.6 years ago
Interventions
Alogliptin/Pioglitazonedrug
Alogliptin/Pioglitazone combination tablets